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Abstract
Background: The world health organization (WHO) declared tuberculosis (TB) a global emergency, mainly affecting
people in sub-Saharan Africa. However there is little data about the burden of TB among adolescents. We estimated the
prevalence and incidence of TB and assessed factors associated with TB among adolescents aged 12–18 years in a rural
population in Uganda in order to prepare the site for phase III clinical trials with novel TB vaccines among adolescents.
Methods: In a prospective cohort study, we recruited 5000 adolescents and followed them actively, every 6 months,
for 1–2 years. Participants suspected of having TB were those who had any of; TB signs and symptoms, history of TB
contact or a positive tuberculin skin test (TST) of ≥10 mm. Laboratory investigations included sputum smear
microscopy and culture.
Results: Of the 5000 participants, eight culture confirmed cases of TB were found at baseline: a prevalence of
160/100,000 (95% confidence interval (CI), 69–315). There were 13 incident TB cases detected in an average of 1.1
person years: an incidence of 235/100,000 person years (95% CI, 125–402). None of the confirmed TB cases were HIV
infected. Predictors for prevalent TB disease were: a history of TB contact and a cough≥ 2 weeks at baseline and being
out of school, while the only predictor for incident TB was a positive TST during follow-up.
Conclusion: The TB incidence among adolescents in this rural part of Uganda seemed too low for a phase III TB
vaccine trial. However, the study site demonstrated capability to handle a large number of participants with minimal
loss to follow-up and its suitability for future clinical trials. Improved contact tracing in TB program activities is likely to
increase TB case detection among adolescents. Future studies should explore possible pockets of higher TB incidence
in urban areas and among out of school youth.
Background
Tuberculosis (TB) is a global emergency causing high
morbidity and mortality especially in sub-Saharan Africa
[1]. The immune response against Mycobacterium tuber-
culosis (MTB) is less effective among adolescents [2].
Adolescents have peculiar clinical TB manifestations and
may present without symptoms but are more likely to
have cavitating disease compared to adults or children [3].
Vaccination against TB using Bacillus Calmette-Guerin
(BCG) in neonates has led to a reduction in incidence of
severe childhood TB and deaths including miliary TB and
TB meningitis [4]. Despite BCG immunization, adult
forms of TB continue to emerge implying the current
vaccine has limited efficacy against adult TB and therefore
a need for new TB vaccines with high protective efficacy
[5-7]. The risk of developing TB following infection starts
to rise from 12–19 years making it a suitable age group
for new TB vaccines [8].
Diagnosed TB among adolescents in most countries is
aggregated and reported together with adult TB cases,
disaggregated as 0–14 and 15–25 years, with limited in-
formation specific to adolescents. Very few studies have
investigated TB prevalence and incidence of TB among
adolescents [9]. Uganda is ranked 16th among the 22 TB
high burden countries globally, with estimated incidence
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rates of about 209 per 100,000 population per year for all
forms of TB in 2010 [10]. The estimated prevalence was
193/100,000 population for all forms of TB in 2010. How-
ever, the country notified an incidence of 128/100,000
population, only 66% of the estimated incidence [1].
The objectives of the study were to estimate the preva-
lence and incidence of TB and assess factors associated
with TB among adolescents aged 12–18 years in a rural
population in Uganda in order to prepare the site for phase
III clinical trials with novel TB vaccines among adolescents.
Methods
The study was conducted in the Makerere University
School of Public Health Demographic Surveillance Site
(DSS) in Iganga and Mayuge districts, located 120 km east
of Kampala between September 2009 and September
2011. The study area is 80% rural and 20% peri-urban with
nine health facilities offering free TB smear microscopy
and treatment. The study area had a population of ap-
proximately 12,000 adolescents aged 12–18 years.
Participants aged 12–18 years who were resident in
the study area for the previous three months were
approached both in school and at home. Those who
gave written assent after the parents/legal guardian had
provided written informed consent were enrolled into
the study. Participants who were planning to move away
from the study area within one year were excluded.
Adolescents were stratified into 12–14 years, 15–16 years
and 17–18 year age groups and conveniently sampled
from schools and in the community with the sample size
in each age stratum proportional to the size of the stratum
population in the DSS. They were recruited consecutively
until the sample size of 5000 was attained. Recruitment
was mainly from rural areas and all had an equal chance
of inclusion in the study. Given the World Health
Organization (WHO) estimated incidence for 2007 of
330/100,000 population at time of study start (September
2009) [10] and 10-20% loss to follow-up; we expected to
find among 5000 adolescents a cumulative TB incidence
of 28 (0.56%) cases in two years, with a 95% CI of {26
(0.37%) - 51 (0.73%)}. These estimates were amended by
WHO downwards in the later reports.
At enrolment, socio-demographic variables, relevant
medical history including symptoms and signs suggestive
of TB were collected. The participant’s weight and
temperature were taken and a physical examination
done. All participants had a tuberculin skin test (TST) 2
Tuberculin Units (Danish type from Staten’s Serum In-
stitute) placed and read after 48–72 hours. Those with a
negative result had a repeat TST done at one and two
years of follow up. Participants were followed up every
6 months for 1–2 years and targeted history and physical
examination were done. The study closed early and there-
fore those recruited later had a shorter duration of follow-
up. Active TB suspicion was defined as participants found
with any one of the following; TST induration of ≥10 mm,
or at least one TB related symptom: cough ≥ 2 weeks,
weight loss for ≥2 weeks, fever for ≥2 weeks, haemoptysis)
or a history of TB contact since the last study follow up
visit. Two sputum samples, a spot sample on day one and
an early morning sample on day 2 were collected from all
TB suspects and transported in cold boxes (temperature
≤8°C) to the reference laboratory within 24 hours. All col-
lected data were entered onto a pre-coded case report
form (CRF).
Laboratory analysis
Sputum samples were processed in the Makerere University
mycobacteriology Biosafety Level III laboratory in Kampala.
All sputum samples were subjected to fluorescence micros-
copy and culture after concentration using 1% sodium hy-
droxide (NAOH)/N-acetyl L-cysteine (NALC) and sodium
citrate method [11]. Cultures were performed by both solid
(Lowenstein-Jensen, (Becton and Dickson, Franklin Lakes,
NJ USA)) and liquid Mycobacterium Growth Indicator
Tube (MGIT) culture techniques and incubated for six to
eight weeks. Species identification was done using Capilia
TB Neo™ (TAUN, Numazu, Japan) assay for all Ziehl-
Neelsen (ZN) positive cultures to exclude mycobacteria
other than tuberculosis (MOTT) and all isolates of myco-
bacterium tuberculosis complex (MTBC) were subjected to
Hain Genotype MTBC assay for speciation. Participants
with at least two positive smears or at least one MTBC cul-
ture were defined as confirmed TB cases.
Ethical approval
Ethical approval was obtained from the Makerere Univer-
sity School of Public Health Higher Degrees Research and
Ethics Committee, the Uganda National Council for Sci-
ence and Technology and the Institutional Review Board of
Institute of Tropical Medicine (ITM) Antwerp of Belgium.
Data analysis
Analysis was done using STATA statistical software (Re-
lease 11.0, Stata Corporation, College Station, Texas,
United States of America). Primary analysis was done by
calculating frequencies for key demographic variables and
overall prevalence and incidence rates; with secondary
analyses done to estimate stratum specific prevalence and
incidence rates by age group, sex, education, schooling
status, TST outcome, TB contact and cough. Person years
were calculated by subtracting the day of entry into the
study from the last day of contact with the participant
divided by 365 days. For those diagnosed with TB, date of
diagnosis was taken as date of last contact. For those who
died, date of death was taken as last date of contact. 95%
confidence intervals (CI) were calculated using Poisson
distribution. Odds ratios (OR) were calculated as a
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measure of TB risk and hazard ratios were calculated for
incident TB cases. In multivariate analysis we included
variables that were significant in univariate analysis at the
P < 0.01 level.
Results
Among the DSS adolescents; 8000 were approached and
5422 (68%) parents agreed to have their children partici-
pate in the study and 5042 (63%) adolescents provided
assent. Among the screened participants, 858 (10.7%)
were ineligible to participate mainly because they were
planning to move away from the study area within one
year. A total of 5000 adolescents were consecutively en-
rolled over a 12 month period. Of these, 1069(21.4%)
were TB suspects at baseline and 1086 (21.7%) during
follow-up. The most common reasons were, a positive
TST 1307 (54.7%), symptoms suggestive of TB 735
(30.8%) and a history of TB contact 441 (18.5%),
Figure 1.
Description of study participants
Study participants were more often male (52%); unmar-
ried (99%), aged 12–14 years (47%), Basoga (82%) the
predominant tribe in the area and majority were in
school (94%), Table 1. A total of 12,124 follow up visits
were planned of which 10,769 (89%) were conducted.
The follow up period was at least 12 months and max-
imum 24 months with an overall loss to follow up of
10.5% and total person years of follow up was 5527 with
mean follow up time of 1.1 person years (SD 0.3). Four
participants died of: juvenile diabetes, tetanus, sickle cell
anemia and a possible cardiac problem and none was
due to TB. A total of 143/5000 (3%) participants were
never seen again after enrollment.
TB prevalence and incidence
A total of nine TB cases out of 5000 adolescents were
detected at baseline of which eight cases were confirmed
microbiologically, Table 2. Of these eight, seven were
Study population
n=5000
TB suspects* (as per 
protocol definition)                                           
n= 2155 (43%)
Non-TB suspects
(Baseline and follow 
up) 
n= 2845 (57%)

























n=21 (0.97%)  
Clinically confirmed 





TB suspects during 
follow up
1086 (21.7%)
* Protocol definition of TB suspect: Cough, fever, weight loss, for more than 2 weeks, or haemoptysis or TST ≥ 10
mm or TB contact at baseline or during follow up.
** Include a case of TB spine and participant already on TB treatment at enrolment based on clinical suspicion.
Figure 1 Study profile and TB cases among adolescents in a rural cohort in eastern Uganda.
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smear (at least 1) and culture positive, and one was
smear negative but culture positive. One of the TB cases
was identified while on TB treatment (smear and culture
positive). This resulted in a crude prevalence of culture
confirmed TB of 160/100,000 (95% CI, 69–315). Of
these eight cases, four had only TB symptoms, three had
only a history of TB contact and one had both symp-
toms and a TB contact. One participant was clinically di-
agnosed with TB in the health facility. This participant
was HIV infected, had TB symptoms and history of TB
contact, but sputum samples were negative on smear
microscopy and culture, Table 2. There were no preva-
lent TB cases among adolescents with a negative TST.
During follow up, 14 cases of TB were detected of
which 13 were culture confirmed (all smear negative)
and one was clinically diagnosed with TB. The average
duration of follow up was 1.1 years. The incidence of
bacteriologically confirmed TB was 235/100,000 person
years (95% CI, 125–402). All TB cases were HIV nega-
tive. Nine (64%) reported no symptoms and none had
CXR abnormalities (CXR was done for only nine cases
after start of treatment for clinical care purposes),
Table 3.
Predictors for prevalent TB
At baseline there was no significant difference in adoles-
cents with bacteriologically confirmed TB by sex, age
groups, and levels of education. Participants who were
out of school were seven times more likely to have TB
than their in-school counter parts (AOR 6.84; 01.28-
36.03). Participants who had contact with a TB patient
were sixteen times more likely to have TB compared to
those with no TB contact (AOR 15.67; 3.57 -68.77).
Those who had had cough for ≥14 days were five times
more likely to have TB than those who had had cough
for ≤14 days or no cough at all (AOR 5.15; 1.20-22.10),
Tables 4 and 5.
Predictors for incident TB
On multivariate analysis, bacteriologically confirmed TB
incidence during follow up was significantly higher
among participants with a positive TST ≥10 mm than
their TST negative counter parts ( adjusted hazard ratio
58.08; 95% CI 7.2-435). The incidence of TB seemed to
increase with age though this trend was not significant,
p-value = 0.093. Incidence was similar among those
with ≥ seven years of schooling compared to those with
lower education level (Adjusted hazard ratio 0.9; 0.20,
Table 1 Baseline characteristics of adolescents enrolled in
the Iganga/Mayuge TB Cohort Study, 2009











>7 years 696 13.9
≤ 7 years 4250 85
Never attended school 14 0.3
Unknown 40 0.8
Enrolment status
In school 4678 94




Table 2 Clinical and laboratory characteristics of prevalent TB cases (n = 9)








1. No Yes Yes Yes Yes Yes Smear and culture
2. Yes No Yes No Yes Yes Smear and culture
3. Yes No Yes Yes Yes Yes Smear and culture
4. Yes No Yes Yes Yes Yes Smear and culture
5. No Yes Yes No Yes Yes Smear and culture
6. No Yes Yes Yes Yes Yes Smear and culture
7. Yes No Yes No Yes Yes Culture only
8. Yes Yes Yes Yes Yes Yes Smear and culture
9. *** Yes Yes Yes Yes No No Clinical diagnosis
Total 6 5 9 6 8 8
*** HIV positive participant.
Abbreviation: Key: TB Tuberculosis, TST Tuberculin Skin Test, CXR Chest X-Ray.
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4.06). Sex specific incidence rates showed males being
three times more likely to develop TB than females
though this difference was also not statistically signifi-
cant (Adjusted hazard ratio 0.32: 0.09-1.17). TB inci-
dence was higher among those who had TB contact and
Table 3 Clinical and laboratory characteristics of the adolescent incident TB cases (n = 14)
Case number Visit detected
(months)








1 12 Yes No Yes Not done No Yes Culture
2 6 Yes No Yes Yes** No No Clinical diagnosis▲
3 12 No No Yes No No Yes Culture
4 12 No No Yes No No Yes Culture
5 12 No Yes Yes No No Yes Culture
6 12 No Yes Yes No No Yes Culture
7 12 No No Yes No No Yes Culture
8 12 No No Yes Not done No Yes Culture
9 12 No No Yes Not done No Yes Culture
10 12 Yes No Yes Not done No Yes Culture
11 24 No No Yes No No Yes Culture
12 24 No No Yes No No Yes Culture
13 12 Yes No Yes No No Yes Culture
14 12 Yes No Yes Not done No Yes Culture
Total 5 2 14 None None 13 14
▲POTTS disease.
1 Culture - all smears were negative.
** Necrosis and collapse of thoracic vertebrae 10–12.
Abbreviation: Key: TB Tuberculosis, TST Tuberculin Skin Test, CXR Chest X-Ray.












Male 3 2589 116 0.419
Female 5 2411 207
Age (yrs)
12-14 4 2339 171
15-16 3 1482 202 0.74
17-18 1 1179 85
Schooling status
Out of school 2 322 621 0.032
In school 6 4678 128
Level of education
> 7 years 1 696 144
≤ 7 years 7 4264 164 0.961
Unknown 0 40 0
Baseline TST
Positive (≥10 mm) 8 802 998
Negative (<10 mm) 0 4179 0 <0.001
Not done / Not Read 0 19 0
TB contact
Yes 4 237 1409 0.115
No 4 4763 76
Cough duration (ever)
Cough <14 days 3 2548 118
No cough 0 1827 0 <0.001
Cough ≥14 days 5 625 800
Abbreviation: Key: TST Tuberculin Skin test.









Female 1.79 0.43 - 7.50 1.74 0.42 - 7.30
Age (yrs)
12-14 Reference Reference
15-16 1.18 0.27 - 5.30 0.95 0.12 - 7.47
17-18 0.5 0.06 - 4.34 0.27 0.02 - 3.72
Schooling status
Out of school 4.87 0.98 - 24.21 6.8 1.28 - 36.03
In school Reference Reference
Level of education
> 7 years Reference Reference
≤ 7 years 1.14 0.14 - 9.30 0.63 0.03 - 13.23
Unknown – –
TB contact (baseline)
Yes 20.42 5.08 - 82.18 15.67 3.57 - 68.77
No Reference Reference
Cough duration (ever)
Cough < 14 days Reference Reference
No cough – –
Cough ≥ 14 days 6.84 1.63 - 28.70 5.15 1.20 - 22.10
Abbreviation: Key: 95% CI 95% Confidence Interval.
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those who had coughed for ≥14 days, but this was not sig-
nificant. Those with incident TB had no prior diagnosis of
TB and were all school-going participants, Tables 6 and 7.
Discussion
Among adolescents 12–18 years of age in a rural setting in
Uganda, we found a prevalence of TB of 160/100,000 and
incidence of 235/100,000 person years. The risk factors for
prevalent TB were TB contact, cough of more than 14 days
and being out of school whereas for incident TB; the only
risk factor was a positive TST ≥ 10 mm.
All incident cases were detected at the scheduled 6
monthly visits and none through the health care system.
This is probably due to active case finding leading to
early detection of cases before they developed symptoms
and presented to the health facilities [3]. All incident
cases were culture positive but smear negative. This
could have been due to sub-clinical colonization with
mycobacteria. Although confidence intervals were
wide, the TB prevalence of 160/100,000 in our sample
was slightly lower than the estimated TB prevalence
for all ages in Uganda (193/100,000). On the other
hand the TB incidence of 235/100,000 person years
was slightly higher than estimated incidence for all
ages in Uganda (209/100,000) [1]. The observed dif-
ferences in rates may be due to low HIV prevalence
in this rural population, active TB case finding and adoles-
cents having a lower TB incidence than the general
population [1].
Table 6 Univariate predictors of incident TB






Total 5000 5527 13 235 -
Follow up TST outcome
*
Negative < 10 mm 2912 3323 1 30
Positive ≥ 10 mm 582 679 11 1620 <0.001
Not done/not read** 1506 1525 1 66
Baseline TST outcome
Negative < 10 mm 4179 4574 12 262 <0.001
Positive ≥ 10 mm 802 890 1 112
Prior diagnosis TB
No 4990 5517 13 236 -
Yes 10 11 0 0
Schooling status
In school 4678 5193 13 250 -
Out of school 322 335 0 0
Age group (years)
12-14 2339 2778 4 144
15-16 1482 1583 4 253 0.093
17-18 1179 1167 5 429
Sex
Male 2589 2898 10 345
Female 2411 2630 3 114 0.028
Education level
> 7 years 696 733 2 273
None 40 37 0 0 0.752
≤ 7 years 4264 4757 11 231
TB Contact during
follow-up
No 4732 5196 11 212 0.019
Yes 268 331 2 604
Cough during follow-up
<14 days 2250 2602 5 192
None 2102 2307 6 260 0.917
≥14 days 500 581 2 344
Abbreviation: Key: Pyrs Person years, TST Tuberculin Skin Test.
Note:
* One individual with TB during follow up had a positive TST of ≥10 mm
at baseline;
**Those with a positive TST at baseline were not given TST again at 1 year and
2 years of follow up.









Follow up TST outcome *
Negative < 10 mm Reference Reference
Positive≥ 10 mm 61.28 7.95 - 472.38 58.08 7.23 - 435.21
Baseline TST outcome
Negative < 10 mm Reference Reference
Positive≥ 10 mm** 1.30 0.37 - 4.63 4.70 0.56 - 39.41
Age group (years)
12-14 Reference Reference
15-16 1.58 0.39 - 6.33 1.58 0.39 - 6.33
17-18 3.49 1.02 - 11.94 2.49 0.67 - 9.28
Sex
Male Reference Reference
Female 0.27 0.08 – 0.95 0.32 0.09 - 1.17
Education level
> 7 years Reference Reference
None




Yes 2.73 0.61 - 12.16
Cough during follow-up
<14 days Reference
None 0.71 0.14 - 3.54
≥14 days 0.78 0.16 - 3.75
Key: 95% CI = 95% Confidence Interval.
Note:
* One individual with TB during follow up had a positive TST of ≥10 mm
at baseline;
**Those with a positive TST at baseline were not given TST again at 1 year and
2 years of follow up.
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Furthermore, our study sample was mainly from a rural
population, prevalence and incidence may have been
much higher if an urban/peri-urban population was sam-
pled. One of the few studies on TB prevalence in Uganda
done in a slum area in Kampala city among chronic
coughers ≥ 15 years reported a TB prevalence of 4,500/
100,000 [12]. Future studies should target adolescents in
crowded settlements in urban centers. Studies done in
adult populations with high HIV prevalence in Africa have
reported higher TB prevalence than our study [13-17].
We did not use CXR to screen TB suspects therefore
we may have underestimated the TB prevalence and in-
cidence in our population. In our study 4265 (85.3%) of
the participants had no TB symptoms. Other prevalence
surveys in the general population (usually among those
aged over 15 years), that used CXR and/or symptoms to
screen for TB have shown that 3852 (23%) of partici-
pants in Western Kenya [13] and 2972 (3.4%) in
Vietnam [18] had CXR abnormalities suggestive of TB.
Risk factors for TB have been shown previously by
others [9,13-15,17]. In our study, risk factors differed
slightly between prevalent and incident cases. The high
prevalence of TB among adolescents with TB contacts
highlights the importance of contact tracing for in-
creased TB case detection mainly in rural areas.
The strength of our study is the relatively large sample
size and the fairly low loss to follow up rate (10.5%).
This high cohort retention is good for potential future
vaccine trials. A weakness of our study however was a
relatively short follow up duration of 1.1 years. It is likely
that a longer follow up would have yielded more TB
cases. Furthermore we did not use chest X-ray as a
screening tool. This may have resulted in underestima-
tion of prevalent TB cases as previous studies docu-
mented an increase in number of TB cases when chest
X-ray results were considered [19-24].
The baseline prevalence may have ‘cleared’ some incident
cases, leading to an underestimation of the incidence.
Moreover, we documented a high refusal rate from parents
and adolescents. As we did not document possible reasons
for refusal, we recommend future studies to explore this.
Conclusion
The TB incidence among adolescents in this rural part of
Uganda seemed too low for a phase III TB vaccine trial. A
positive tuberculin test ≥10 mm, a history of TB contact and
a cough ≥ 14 days are the major predictors for TB disease.
However, the study demonstrated the capability of the study
site to handle a large number of participants with minimal
loss to follow-up which is important for future clinical trials.
Improved contact tracing in TB program activities is likely
to increase TB case detection among adolescents. Future
studies should explore possible pockets of higher TB inci-
dence in urban areas and among out of school youth.
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